journal article·2020-03-20Open access

Mechanical and physio-biological properties of peptide-coated stent for re-endothelialization

In-Ho Bae, Myung Ho Jeong, Dae Sung Park, Kyung Seob Lim, Jae Won Shim, Mun Ki Kim, Jun-Kyu Park

Biomaterials Research· Volume 24· Issue 1

Abstract

Abstract Background The aim of this study was to characterize the mechanical and physio-biological properties of peptide-coated stent (PCS) compared to commercialized drug-eluting stents (DESs). Methods WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met), a stimulating peptide for homing endothelial colony-forming cell was specially synthesized and coated to bare metal stent (BMS) by dopamine-derived coordinated bond. Biological effects of PCS were investigated by endothelial cell proliferation assay and pre-clinical animal study. And mechanical properties were examined by various experiment. Results The peptide was well-coated to BMS and was maintained and delivered to 21 and 7 days in vitro and in vivo, respectively. Moreover, the proliferation of endothelial cell in PCS group was increased (approximately 36.4 ± 5.77%) in PCS group at 7 day of culture compare to BMS. Although, the radial force of PCS was moderated among study group. The flexibility of PCS was (0.49 ± 0.082 N) was greatest among study group. PCS did not show the outstanding performance in recoil and foreshortening test (3.1 ± 0.22% and 2.1 ± 0.06%, respectively), which was the reasonable result under the guide line of FDA (less than 7.0%). The nominal pressure (3.0 mm in a diameter) of PCS established by compliance analysis was 9 atm. The changing of PCS diameter by expansion was similar to other DESs, which is less than 10 atm of pressure for the nominal pressure. Conclusions These results suggest that the PCS is not inferior to commercialized DES. In addition, since the PCS was fabricated as polymer–free process, secondary coating with polymer-based immunosuppressive drugs such as –limus derivatives may possible.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Coronary Interventions and Diagnostics · Polymer Surface Interaction Studies · Angiogenesis and VEGF in Cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cardiovascular Convergence Research Center of Chonnam National University Hospital Designated by Korea Ministry of Health and Welfare, Jaebongro 671, Dong-gu, Gwangju 61469, Republic of Korea.

Korea Cardiovascular Stent Research Institute, Jangsung 57248, Republic of Korea.

Department of Cardiology, Chonnam National University Hospital, Gwangju 61469, Republic of Korea.

Cardiovascular Convergence Research Center of Chonnam National University Hospital, Gwangju 57248, Republic of Korea.

National Primate Research Center & Futuristic Animal Resource and Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang 28116, Republic of Korea.

CGBio Co. Ltd., Jangseong 57248, Republic of Korea.

Funding

Ministry of SMEs and Startups · Ministry of Health & Welfare, Republic of Korea

References (42)

Show source-provided references
1. 10.1056/NEJMra05109110.1056/NEJMra051091 ↗
2. 10.1161/01.CIR.0000071083.31270.C310.1161/01.CIR.0000071083.31270.C3 ↗
3. 10.1016/j.jacc.2006.03.04210.1016/j.jacc.2006.03.042 ↗
4. 10.1016/S0735-1097(97)00049-110.1016/S0735-1097(97)00049-1 ↗
5. 10.1161/01.CIR.0000133324.38115.0A10.1161/01.CIR.0000133324.38115.0A ↗
6. Le Y, Gong W, Li B, Dunlop NM, Shen W, Su SB, Ye RD, Wang JM. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol. 1999;163(12):6777–6784. 1:CAS:528:DyaK1MXotFShtr8%3D10.4049/jimmunol.163.12.6777 ↗
7. 10.1016/S0009-9120(97)00172-010.1016/S0009-9120(97)00172-0 ↗
8. 10.1002/stem.157810.1002/stem.1578 ↗
9. 10.4049/jimmunol.178.11.739510.4049/jimmunol.178.11.7395 ↗
10. 10.1002/jbm.b.3191110.1002/jbm.b.31911 ↗
11. 10.1016/j.jacc.2009.05.07510.1016/j.jacc.2009.05.075 ↗
12. 10.1093/ehjci/jet27310.1093/ehjci/jet273 ↗
13. 10.1161/01.CIR.101.21.247810.1161/01.CIR.101.21.2478 ↗
14. 10.1161/01.RES.84.4.37810.1161/01.RES.84.4.378 ↗
15. 10.1007/s00270991000710.1007/s002709910007 ↗
16. 10.1007/s10047-008-0456-x10.1007/s10047-008-0456-x ↗
17. 10.1002/jbm.b.3102810.1002/jbm.b.31028 ↗
18. 10.1016/j.biomaterials.2006.11.04210.1016/j.biomaterials.2006.11.042 ↗
19. 10.1583/10-3069.110.1583/10-3069.1 ↗
20. 10.1002/ccd.2216610.1002/ccd.22166 ↗
21. 10.4068/cmj.2013.49.1.710.4068/cmj.2013.49.1.7 ↗
22. Bae IH Lim KS Park JK Park DS Lee SY Jang EJ Ji MS. Mechanical behavior and in vivo properties of newly designed bare metal stent for enhanced flexibility. J Indust Eng Chem in press. 2014.10.1016/j.jiec.2014.05.045 ↗
23. Buszman P, Trznadel S, Zurakowski A, Milewski K, Kinasz L, Krol M, Kondys M. Prospective registry evaluating safety and efficacy of cobalt-chromium stent implantation in patients with de novo coronary lesions. Kardiol Pol. 2007;65(9):1041–1046. discussion 1047-8.
24. Seo JK, Choi SY, Kim Y, Baek SH, Kim KT, Chae CB, Lambeth JD, Suh PG, Ryu SH. A peptide with unique receptor specificity: stimulation of phosphoinositide hydrolysis and induction of superoxide generation in human neutrophils. J Immunol. 1997;158(4):1895–1901. 1:CAS:528:DyaK2sXhtF2msrc%3D10.4049/jimmunol.158.4.1895 ↗
25. 10.1021/bc200053410.1021/bc2000534 ↗
26. 10.1007/s10856-012-4587-510.1007/s10856-012-4587-5 ↗
27. 10.1016/0003-2697(90)90675-Y10.1016/0003-2697(90)90675-Y ↗
28. 10.1016/j.jpba.2010.10.02710.1016/j.jpba.2010.10.027 ↗
29. 10.1038/bjc.1987.19010.1038/bjc.1987.190 ↗
30. 10.1016/S1051-0443(07)60015-310.1016/S1051-0443(07)60015-3 ↗
31. 10.4244/EIJV4I3A6810.4244/EIJV4I3A68 ↗
32. 10.1161/01.CIR.103.23.281610.1161/01.CIR.103.23.2816 ↗
33. 10.1161/01.CIR.101.7.81210.1161/01.CIR.101.7.812 ↗
34. Lau KW, Johan A, Sigwart U, Hung JS. A stent is not just a stent: stent construction and design do matter in its clinical performance. Singap Med J. 2004;45(7):305–311. 1:STN:280:DC%2BD2czitVWhsg%3D%3D. quiz 312.
35. McLean DR, Eiger NL. Stent design: implications for restenosis. Rev Cardiovasc Med. 2002;3(Suppl 5):S16–S22.
36. 10.1016/j.patbio.2004.03.01310.1016/j.patbio.2004.03.013 ↗
37. 10.1016/S0002-9149(00)01268-610.1016/S0002-9149(00)01268-6 ↗
38. 10.1016/j.biomaterials.2007.03.02010.1016/j.biomaterials.2007.03.020 ↗
39. 10.1016/j.toxlet.2006.11.01310.1016/j.toxlet.2006.11.013 ↗
40. 10.1016/j.jacc.2008.08.02410.1016/j.jacc.2008.08.024 ↗
41. 10.1016/j.biomaterials.2008.12.07510.1016/j.biomaterials.2008.12.075 ↗
42. 10.1114/1.145859410.1114/1.1458594 ↗